Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24962979 | 0.95 | GPR119 (0.55) | GPR119HPGDSMN1; SMN2MAPTPTPN11 | |
| SCHEMBL31410468 | 0.91 | HPGD (0.55) | GPR119HPGDSMN1; SMN2MAPT | |
| SCHEMBL30859784 | 0.89 | GPR119 (0.50) | GPR119HPGDSMN1; SMN2MAPTPTPN11 | |
| SCHEMBL13009471 | 0.89 | GPR119 (0.60) | GPR119SMN1; SMN2MAPTPTPN11CKS1B | |
| SCHEMBL6785524 | 0.88 | GPR119 (0.66) | GPR119HPGDSMN1; SMN2MAPTPTPN11 | |
| SCHEMBL29165898 | 0.88 | GPR119 (0.59) | GPR119SMN1; SMN2MAPTPTPN11CKS1B | |
| SCHEMBL30859957 | 0.87 | GPR119 (0.48) | GPR119HPGDSMN1; SMN2MAPTPTPN11 | |
| SCHEMBL30859951 | 0.87 | GPR119 (0.48) | GPR119HPGDSMN1; SMN2MAPTPTPN11 | |
| SCHEMBL29168944 | 0.86 | GPR119 (0.50) | GPR119HPGDSMN1; SMN2MAPTTIPARP | |
| SCHEMBL29169128 | 0.86 | GPR119 (0.50) | GPR119HPGDSMN1; SMN2MAPTTIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | RIBON THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-119968364-A | Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds | 阿兹卡拉疗法公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025045246-A1 | PARP7 INHIBITOR AND USE THEREOF | 重庆华森英诺生物科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| CN-116535395-B | 2H-indazole-7-carboxamide compounds, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-07-09 | — | — | CN | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20220162196-A1 | SOLID FORMS OF A PARP7 INHIBITOR | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2022-05-26 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112424188-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020223229-A1 | SOLID FORMS OF A PARP7 INHIBITOR | RIBON THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-20220162196-A1 | SOLID FORMS OF A PARP7 INHIBITOR | PARP1, PARP2, PARP4 | GPR119 4367/4885HPGD 1438/4885SMN1; SMN2 2461/4885 |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | PARP1, PARP2, PARP4 | GPR119 4367/4885HPGD 1438/4885SMN1; SMN2 2461/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | GPR119 3786/4885HPGD 2503/4885SMN1; SMN2 889/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | GPR119 2414/4885HPGD 739/4885SMN1; SMN2 3311/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | GPR119 4379/4885HPGD 463/4885SMN1; SMN2 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.